Vertex Pharmaceuticals Incorporated: Profit on the Horizon

Vertex Pharmaceuticals (NASDAQ:VRTX) released outstanding third-quarter earnings on Wednesday with sales of both cystic fibrosis drugs, Orkambi and Kalydeco, selling like hotcakes. Continue reading Vertex Pharmaceuticals Incorporated: Profit on the Horizon

Vertex Turns Up the Heat on Cystic Fibrosis Challengers

Back in 2012, Vertex Pharmaceuticals (NASDAQ:VRTX) changed thousands of lives when it won approval to market Kalydeco to treat cystic fibrosis patients in the U.S. and EU. Cystic fibrosis, or CF, can be caused by one of many mutations Continue reading Vertex Turns Up the Heat on Cystic Fibrosis Challengers

Galapagos advances triple combination therapy in cystic fibrosis

GLPG2665, a next-generation (C2) corrector, together with the other two components of the triple combination, show up to six-fold greater chloride transport than Orkambi1) in vitro

– Triple combination therapy of C2 with GLPG2222 and GLPG1837 expected to Continue reading Galapagos advances triple combination therapy in cystic fibrosis